Opus Genetics Reports Vision Improvement in Phase 1/2 OPGx-BEST1 Trial

08:02 AM EDT, 09/09/2026 (MT Newswires) -- Opus Genetics (IRD) said Wednesday that patients with Bestrophin-1-related retinal diseases showed clinically meaningful improvement in visual function in the low-dose cohort 1 of its BIRD-1 phase 1/2 clinical trial evaluating OPGx-BEST1. The biopharmaceutical company said the five participants in the trial with BEST1-related retinal diseases showed meaningful visual improvements. It also said four of the five patients showed structural improvements. There were no serious adverse events, dose-limiting toxicities, or intraocular inflammation reported in the trial.